NCT06627647 2026-03-27A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLCAstraZenecaPhase 3 Recruiting878 enrolled